Page last updated: 2024-11-04

sb 202190 and Carcinoma, Epidermoid

sb 202190 has been researched along with Carcinoma, Epidermoid in 2 studies

4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole: structure given in first source; inhibits p38 MAP kinase

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ko, JC1
Chiu, HC1
Wo, TY1
Huang, YJ1
Tseng, SC1
Huang, YC1
Chen, HJ1
Syu, JJ1
Chen, CY1
Jian, YT1
Jian, YJ1
Lin, YW1
Hill, NT1
Zhang, J1
Leonard, MK1
Lee, M1
Shamma, HN1
Kadakia, M1

Other Studies

2 other studies available for sb 202190 and Carcinoma, Epidermoid

ArticleYear
Inhibition of p38 MAPK-dependent MutS homologue-2 (MSH2) expression by metformin enhances gefitinib-induced cytotoxicity in human squamous lung cancer cells.
    Lung cancer (Amsterdam, Netherlands), 2013, Volume: 82, Issue:3

    Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemotherapy, Adjuvan

2013
1α, 25-Dihydroxyvitamin D₃ and the vitamin D receptor regulates ΔNp63α levels and keratinocyte proliferation.
    Cell death & disease, 2015, Jun-11, Volume: 6

    Topics: Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival

2015